DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07, Bloomberg Earnings reports. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. During the same quarter in the previous year, the company earned ($0.24) earnings per share. The business’s revenue was up 24.3% compared to the same quarter last year.
Shares of DexCom (NASDAQ:DXCM) traded up 0.58% during mid-day trading on Friday, reaching $73.20. The company’s stock had a trading volume of 1,234,880 shares. The company has a 50-day moving average of $70.65 and a 200-day moving average of $74.91. The firm’s market cap is $6.34 billion. DexCom has a 12 month low of $57.68 and a 12 month high of $96.38.
WARNING: This piece of content was reported by BNB Daily and is owned by of BNB Daily. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.baseball-news-blog.com/2017/08/19/dexcom-inc-dxcm-releases-earnings-results-beats-estimates-by-0-06-eps-updated-updated.html.
In related news, EVP Andrew K. Balo sold 3,200 shares of DexCom stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $69.06, for a total value of $220,992.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $69.77, for a total value of $418,620.00. The disclosure for this sale can be found here. Insiders have sold 33,726 shares of company stock worth $2,376,466 over the last three months. Insiders own 1.70% of the company’s stock.
Several institutional investors have recently bought and sold shares of DXCM. Dimensional Fund Advisors LP raised its position in DexCom by 4.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 110,292 shares of the medical device company’s stock worth $6,586,000 after buying an additional 4,682 shares in the last quarter. Norges Bank bought a new position in DexCom during the fourth quarter worth approximately $27,815,000. Teachers Advisors LLC raised its position in DexCom by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 184,560 shares of the medical device company’s stock worth $11,018,000 after buying an additional 7,050 shares in the last quarter. Highbridge Capital Management LLC bought a new position in DexCom during the fourth quarter worth approximately $2,983,000. Finally, Chevy Chase Trust Holdings Inc. bought a new position in DexCom during the first quarter worth approximately $3,600,000.
Several equities research analysts have recently commented on DXCM shares. Canaccord Genuity restated a “buy” rating and issued a $90.00 target price on shares of DexCom in a research note on Wednesday, June 7th. Oppenheimer Holdings, Inc. set a $98.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Wednesday, May 3rd. TheStreet upgraded shares of DexCom from a “d” rating to a “c-” rating in a research note on Wednesday, August 2nd. Piper Jaffray Companies restated an “overweight” rating and issued a $78.00 target price on shares of DexCom in a research note on Monday, May 22nd. Finally, BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $87.00.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.